Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Generate Biomedicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Generate Biomedicines, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336437
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Net cash used in operating activities | (138,332) | (101,929) |
| Investing activities | ||
| Purchase of marketable securities | (321,759) | (142,508) |
| Purchases of property and equipment | (4,714) | (905) |
| Proceeds from sales and maturities of marketable securities | 99,850 | 201,877 |
| Net cash (used in) provided by investing activities | (226,623) | 58,464 |
| Financing activities | ||
| Proceeds from issuance of convertible preferred stock, net of issuance costs | — | 21,972 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Generate Biomedicines, Inc.'s capex?
- Generate Biomedicines, Inc. (GENB) reported capex of $933K in Q2 2026.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Generate Biomedicines, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude